14 withdrawn. 14 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Withdrawn 14 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Abnormalities, Multiple: new trials by email Literature Review of Abnormalities, Multiple trials Research Report on Abnormalities, Multiple
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome Sargramostim for Injection, Saline Placebo - Down Syndrome | Phase 2 | Withdrawn | University of Colorado, Denver | 2023-10-23 | 2025-04-02 | |
| An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) NNZ-2591 - Prader-Willi Syndrome | Phase 2 | Withdrawn | Neuren Pharmaceuticals Limited | 2023-09-01 | 2024-12-09 | |
| 12-week Study of NFX-179 Gel in Subjects With Epidermal Nevi NFX-179 Gel 1.50% - Epidermal Nevi, Nevus Sebaceus | Phase 2 | Withdrawn | Albert Chiou | 2023-06-01 | 2024-05-28 | |
| Mitochondrial Complex I Dysfunction in PWS Coenzyme Q10, Placebo - Prader-Willi Syndrome | Phase 2 | Withdrawn | The Hospital for Sick Children | 2023-06-01 | 2024-06-18 | |
| Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome Placebo, Tesomet - Prader-Willi Syndrome | Phase 2 | Withdrawn | Saniona | 2021-12-28 | 2022-12-13 | |
| A Study of ACI-24 in Adults With Down Syndrome ACI-24, Placebo - Down Syndrome | Phase 2 | Withdrawn | AC Immune SA | 2021-10-01 | 2021-10-22 | |
| tVNS in Children With Prader-Willi Syndrome tVNS - Prader-Willi Syndrome, Social Behavior | Phase 1 / Phase 2 | Withdrawn | Stanford University | 2020-07-01 | 2021-05-06 | |
| Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome Vismodegib, Nivolumab, Ipilimumab - Basal Cell Nevus Syndrome | Phase 2 | Withdrawn | Columbia University | 2019-07-01 | 2019-12-18 | |
| Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement Metformin - Bardet-Biedl Syndrome, Visual Impairment | Phase 2 | Withdrawn | University Hospital Tuebingen | 2018-04-01 | 2019-04-18 | |
| A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR) Diazoxide choline controlled-release tablet - Prader-Willi Syndrome | Phase 2 | Withdrawn | Essentialis, Inc. | 2017-07-01 | 2026-11-17 | |
| An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder EPI-743 - Autism Spectrum Disorder | Phase 2 | Withdrawn | Edison Pharmaceuticals Inc | 2014-10-31 | 2022-01-21 | |
| Novel Treatment for Syndromic Ichthyoses Lovastatin - Syndromic Ichthyoses, CHILD Syndrome | Phase 2 | Withdrawn | Northwestern University | 2011-07-01 | 2015-05-19 | |
| Liq-NOL Efficacy in Pediatric Patients With Down Syndrome Ubiquinol-10 Syrup, syrup (placebo) - Down Syndrome | Phase 2 | Withdrawn | Children's Hospital Medical Center, Cincinnati | 2005-01-01 | 2020-09-09 | |
| Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) LDE225B, Vehicle - Basal Cell Carcinoma | Phase 2 / Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2017-05-05 |
Prader-Willi Syndrome (5) · Down Syndrome (3) · Basal Cell Nevus Syndrome (2) · Angelman Syndrome (1) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Bardet-Biedl Syndrome (1) · Behavior (1) · Carcinoma, Basal Cell (1) · Cognitive Dysfunction (1) · Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects (1) · Hyperphagia (1) · Language (1) · Mitochondrial Diseases (1) · Nevus, Sebaceous of Jadassohn (1)
Congenital Abnormalities (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Genetic Diseases, Inborn (13) · Nervous System Diseases (11) · Neurologic Manifestations (10) · Chromosome Disorders (9) · Intellectual Disability (9) · Neurobehavioral Manifestations (9) · Nutritional and Metabolic Diseases (7) · Imprinting Disorders (6) · Nutrition Disorders (5) · Obesity (5) · Overnutrition (5) · Overweight (5)
Granulocyte-Macrophage Colony-Stimulating Factor (1) · HhAntag691 (1) · Injections (1) · Ipilimumab (1) · Lovastatin (1) · Metformin (1) · Metoprolol (1) · Nivolumab (1) · Tesofensine (1) · alpha-tocotrienol quinone (1) · coenzyme Q10 (1) · cyclo-L-glycyl-L-2-allylproline (1) · sargramostim (1)
AC Immune SA (1) · Albert Chiou (1) · Children's Hospital Medical Center, Cincinnati (1) · Columbia University (1) · Edison Pharmaceuticals Inc (1) · Essentialis, Inc. (1) · Neuren Pharmaceuticals Limited (1) · Northwestern University (1) · Novartis Pharmaceuticals (1) · Saniona (1) · Stanford University (1) · The Hospital for Sick Children (1) · University Hospital Tuebingen (1) · University of Colorado, Denver (1)
United States (5) · Canada (2) · Belgium (1) · Czechia (1) · Finland (1) · Germany (1) · Greece (1) · Italy (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Albert S Chiou, MD, MBA (1) · Amy S Paller, MD (1) · Francis Hickey, M.D. (1) · Heiko Billing, PD Dr. med. (1) · Ingrid Tein, MD (1) · Jordan Press (1) · Michael S. Rafii, MD, PhD (1) · Michael V Miles, Pharm.D. (1) · Peter Pressman, MD (1) · Richard Carvajal, MD. (1) · Sophie Guillaume, MS (1)
R61AG074859 (1)